Streetbeat News

Revenues

RUN

Sunrun (NASDAQ:RUN) has been the subject of diverse analyst ratings over the past three months, with 13 analysts offering a range of opinions. The average 12-month price target is $21.46, with a high of $35.00 and a low of $12.00, marking an 8.91% decrease in the average target. Recent actions include both raised and lowered price targets and ratings, reflecting dynamic market conditions and company performance. Sunrun's financials show a -10.88% revenue decline over 3 months, a net margin of -189.9%, an ROE of -17.52%, an ROA of -5.28%, and a high debt-to-equity ratio of 1.9.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:01 pm

ZUO

In the last three months, 4 analysts have provided ratings on Zuora (NYSE:ZUO), with all maintaining a bullish stance. The average 12-month price target is $14.5, representing a 45% increase from the previous target of $10. Zuora's financial performance shows positive revenue growth, a strong net margin, and an excellent ROE and ROA, but a high debt-to-equity ratio. Analysts from Goldman Sachs, Needham, and Canaccord Genuity have recently updated their ratings and price targets for ZUO.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:01 pm

ADM

Archer-Daniels Midland (NYSE:ADM) has been the subject of 10 analyst ratings over the past three months, with a shift towards a more bearish sentiment. The average 12-month price target has been reduced by 27.15%, with the current average at $70.3. Analysts from firms including Goldman Sachs, Stifel, Barclays, Roth MKM, BMO Capital, Baird, UBS, and Morgan Stanley have lowered their price targets. ADM's financial performance shows a decline in revenue growth by -12.11% over the past 3 months, but it maintains strong net margin, ROE, and ROA figures, and a conservative debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:00 pm

SEDG

SolarEdge Technologies (NASDAQ:SEDG) has received mixed ratings from 21 financial analysts, with a current average 12-month price target of $79.28, down 32.82% from the previous $118.01. Ratings range from 'Buy' to 'Sell', with recent actions including both upgrades and downgrades. The company's financial performance shows a -13.32% decline in revenue growth, a net margin of -8.43%, ROE of -2.44%, ROA of -1.31%, and a debt-to-equity ratio of 0.29.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 6:00 pm

DTSS

Datasea's stock (DTSS) is trading higher following the company's pre-announcement of its first half 2024 revenue, indicating a positive financial outlook.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 5:41 pm

ESGL

ESGL Holdings' stock price is on the rise following the announcement of a multi-year circular NEWSPAR supply agreement with Sentosa Clay Products. This agreement is expected to provide a stable and potentially growing revenue stream for ESGL Holdings over the duration of the contract.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 5:32 pm

CTRA

Analysts have provided mixed ratings for Coterra Energy (NYSE:CTRA) with 3 bullish, 2 somewhat bullish, and 1 indifferent rating. The average 12-month price target is $32.17, with a high of $39.00 and a low of $30.00, indicating a 3.77% increase from the previous target of $31.00. Recent actions include maintaining, raising, and lowering ratings and price targets. Coterra, an independent exploration and production company, has a lower market cap compared to peers, faced a significant revenue decline of -46.19% over 3 months, but has a strong net margin of 23.75%. However, it has below-average ROE and ROA, and a conservative debt-to-equity ratio of 0.2.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 5:00 pm

NVO

EraCal Therapeutics has entered into a collaboration with Novo Nordisk to develop and commercialize EraCal's oral small molecule program for treating obesity. The deal includes upfront, development, and commercial milestones that could total up to €235 million.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:47 pm

IVZ

Invesco's stock price is trading lower following the announcement of their fourth-quarter revenue results, which fell short of market expectations.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:22 pm

PLTR

Palantir Technologies (NYSE:PLTR) is evaluated against competitors in the Software industry. With a P/E ratio of 251.43, P/B of 12.01, and P/S of 18.50, Palantir is priced at a premium and may be overvalued compared to peers. Its ROE of 2.33% and EBITDA of $0.09 billion are below the industry average, indicating potential inefficiencies. However, its revenue growth of 16.8% surpasses the industry average, suggesting strong sales performance. Palantir's lower debt-to-equity ratio of 0.07 indicates a strong financial position with less reliance on debt.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 4:01 pm